130 related articles for article (PubMed ID: 36072283)
1. Efficacy of avelumab plus axitinib for advanced renal cell carcinoma as late-line therapy: A case report.
Uekawa A; Kurahashi R; Motoshima T; Murakami Y; Yatsuda J; Kamba T
Urol Case Rep; 2022 Nov; 45():102198. PubMed ID: 36072283
[TBL] [Abstract][Full Text] [Related]
2. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI
Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667
[TBL] [Abstract][Full Text] [Related]
3. A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib.
Suzuki I; Kijima T; Takada-Owada A; Nakamura G; Uematsu T; Sakamoto K; Nishihara D; Ishida K; Kamai T
IJU Case Rep; 2021 Nov; 4(6):412-416. PubMed ID: 34755071
[TBL] [Abstract][Full Text] [Related]
4. Avelumab plus Axitinib for the Treatment of Patients with End-Stage Renal Disease Undergoing Dialysis: A Retrospective Case Series and Literature Review.
Bando Y; Furukawa J; Hara T; Okamura Y; Terakawa T; Nakano Y; Fujisawa M
Urol Int; 2023; 107(3):321-326. PubMed ID: 36731453
[TBL] [Abstract][Full Text] [Related]
5. A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma.
Lu P; Liang W; Li J; Hong Y; Chen Z; Liu T; Dong P; Huang H; Zhang T; Jiang J
Front Pharmacol; 2020; 11():619. PubMed ID: 32457618
[TBL] [Abstract][Full Text] [Related]
6. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Motzer RJ; Penkov K; Haanen J; Rini B; Albiges L; Campbell MT; Venugopal B; Kollmannsberger C; Negrier S; Uemura M; Lee JL; Vasiliev A; Miller WH; Gurney H; Schmidinger M; Larkin J; Atkins MB; Bedke J; Alekseev B; Wang J; Mariani M; Robbins PB; Chudnovsky A; Fowst C; Hariharan S; Huang B; di Pietro A; Choueiri TK
N Engl J Med; 2019 Mar; 380(12):1103-1115. PubMed ID: 30779531
[TBL] [Abstract][Full Text] [Related]
7. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.
Choueiri TK; Motzer RJ; Rini BI; Haanen J; Campbell MT; Venugopal B; Kollmannsberger C; Gravis-Mescam G; Uemura M; Lee JL; Grimm MO; Gurney H; Schmidinger M; Larkin J; Atkins MB; Pal SK; Wang J; Mariani M; Krishnaswami S; Cislo P; Chudnovsky A; Fowst C; Huang B; di Pietro A; Albiges L
Ann Oncol; 2020 Aug; 31(8):1030-1039. PubMed ID: 32339648
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101.
Tomita Y; Motzer RJ; Choueiri TK; Rini BI; Miyake H; Uemura H; Albiges L; Fujii Y; Umeyama Y; Wang J; Mariani M; Schmidinger M
ESMO Open; 2022 Apr; 7(2):100450. PubMed ID: 35397432
[TBL] [Abstract][Full Text] [Related]
9. Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report.
Katsumata Y; Kawasaki Y; Tanaka K; Nakayama D; Katayama H; Shimada S; Satake Y; Sato T; Kawamorita N; Yamashita S; Sato T; Shoji K; Mitsuzuka K; Ito A
Case Rep Oncol; 2021; 14(3):1522-1529. PubMed ID: 34899246
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial.
Choueiri TK; Larkin J; Pal S; Motzer RJ; Rini BI; Venugopal B; Alekseev B; Miyake H; Gravis G; Bilen MA; Hariharan S; Chudnovsky A; Ching KA; Mu XJ; Mariani M; Robbins PB; Huang B; di Pietro A; Albiges L
ESMO Open; 2021 Jun; 6(3):100101. PubMed ID: 33901870
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma.
Hamamoto S; Tasaki Y; Morikawa T; Naiki T; Etani T; Taguchi K; Iwatsuki S; Unno R; Takeda T; Nagai T; Kawase K; Mimura Y; Sugiyama Y; Okada A; Furukawa-Hibi Y; Yasui T
J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38929893
[No Abstract] [Full Text] [Related]
12. A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma.
Tiako Meyo M; Chen J; Goldwasser F; Hirsch L; Huillard O
Ther Clin Risk Manag; 2022; 18():683-698. PubMed ID: 35837579
[TBL] [Abstract][Full Text] [Related]
13. Avelumab plus axitinib therapy for renal cell carcinoma in a patient with pulmonary alveolar proteinosis: A case report.
Shimizu N; Hasumi M; Muramatsu K; Tsuji Y; Takaku Y
Urol Case Rep; 2021 Nov; 39():101843. PubMed ID: 34540590
[TBL] [Abstract][Full Text] [Related]
14. A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX).
Bex A; van Thienen JV; Schrier M; Graafland N; Kuusk T; Hendricksen K; Lagerveld B; Zondervan P; van Moorselaar JA; Blank C; Wilgenhof S; Haanen J
Future Oncol; 2019 Jul; 15(19):2203-2209. PubMed ID: 31023100
[TBL] [Abstract][Full Text] [Related]
15. Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy.
Leslie I; Boos LA; Larkin J; Pickering L
Expert Rev Anticancer Ther; 2020 May; 20(5):343-354. PubMed ID: 32293937
[No Abstract] [Full Text] [Related]
16. Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial.
Kudo M; Motomura K; Wada Y; Inaba Y; Sakamoto Y; Kurosaki M; Umeyama Y; Kamei Y; Yoshimitsu J; Fujii Y; Aizawa M; Robbins PB; Furuse J
Liver Cancer; 2021 Jun; 10(3):249-259. PubMed ID: 34239811
[TBL] [Abstract][Full Text] [Related]
17. [COMPLETE REMISSION OF METASTATIC RENAL CELL CARCINOMA AFTER PARTIAL NEPHRECTOMY FOLLOWING PEMBROLIZUMAB PLUS AXITINIB THERAPY: A CASE REPORT].
Hakamata Y; Uchida K; Noda T; Imai S; Yoneda T; Kudoh S
Nihon Hinyokika Gakkai Zasshi; 2022; 113(4):139-142. PubMed ID: 37866934
[TBL] [Abstract][Full Text] [Related]
18. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis.
Cao G; Wu X; Wang Z; Tian X; Zhang C; Wu X; Zhang H; Jing G; Yan T
BMJ Open; 2020 Aug; 10(8):e034626. PubMed ID: 32859659
[TBL] [Abstract][Full Text] [Related]
19. Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report.
Koie T; Ohyama C; Okamoto A; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y
BMC Res Notes; 2013 Nov; 6():484. PubMed ID: 24267160
[TBL] [Abstract][Full Text] [Related]
20. [Complete Remission of Metastatic Renal Cell Carcinoma with Invasion of the Duodenum and Pancreas after Treatment with Nivolumab Plus Ipilimumab Followed by Axitinib and Surgery : A Case Report].
Hagimoto H; Yamazaki T; Kashima S; Yoshino T; Goto T; Sano T; Sawada A; Akamatsu S; Kobayashi T; Nakano K; Yagi S; Matsuoka Y; Fujimoto M; Kitamura T; Ogawa O
Hinyokika Kiyo; 2021 May; 67(5):197-203. PubMed ID: 34126663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
